Tag Archives: qnexa

Shortly after recommending approval of Qnexa (Phentermine / Topiramate), the FDA advisory panel this week also voted to approve Arena Pharmaceuticals weight loss drug, Lorgess (Lorcacerin). This medication has been in clinical trials over the past several years and works through the 5HT2c sub-type Seratonin receptor in the brain. Why is this important? What is […]

Today the FDA announced that instead of reviewing Qnexa, the new weight loss drug by Vivus, combining Phentermine and Topiramate, they are pushing back the review date by 3 months to July 17th, 2012, to allow time to review all of the submitted data that Vivus provided the FDA. “MOUNTAIN VIEW, Calif., April 9, 2012 […]

On February 22nd, 2012, the Advisory Committee to the FDA met to review a new weight loss drug, Qnexa. This drug is a combination of Phentermine and Topiramate, and the combination yields substantially better weight loss than Phentermine alone, even with lower doses of Phentermine. In 2010, the same advisory committee voted against Qnexa, and […]

The FDA is again considering approval of an experimental weight loss drug it rejected a year ago over concerns about potential heart problems and birth defects in babies born to women who take the drug.   California-based pharmaceutical company Vivus Inc, is now asking for limited approval for its oral combination drug Qnexa, which would […]